Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC8 | Q09428 | 12/20 | 0.44 |
| ▸ | KCNJ11 | Q14654 | 12/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7079077 | 0.92 | ABCC8 (0.43) | ABCC8KCNJ11ADRA2AADRA2BADRA2C | |
| SCHEMBL7593117 | 0.91 | ABCC8 (0.42) | ABCC8KCNJ11 | |
| SCHEMBL7074970 | 0.90 | ABCC8 (0.41) | ABCC8KCNJ11 | |
| SCHEMBL7080805 | 0.90 | ABCC8 (0.41) | ABCC8KCNJ11 | |
| SCHEMBL6802723 | 0.90 | ABCC8 (0.41) | ABCC8KCNJ11 | |
| SCHEMBL6802837 | 0.89 | ABCC8 (0.43) | ABCC8KCNJ11GRIA1GRIA2GRIA3 | |
| SCHEMBL8478611 | 0.88 | ABCC8 (0.41) | ABCC8KCNJ11 | |
| SCHEMBL7077490 | 0.87 | ADRA2A (0.36) | ABCC8KCNJ11ADRA2AADRA2BADRA2C | |
| SCHEMBL7077815 | 0.86 | ABCC8 (0.41) | ABCC8KCNJ11GRIA1GRIA2GRIA3 | |
| SCHEMBL7570046 | 0.85 | ADRA2A (0.37) | ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030235583-A1 | Combined use of a modulator of CD3 and a beta cell resting compound | NOVO NORDISK A/S (DK) | 2003-12-25 | — | — | US | claimed |
| US-20030125323-A1 | Use of selective potassium channel openers | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | US | claimed |
| US-20030109519-A1 | Use of selective potassium channel openers | NOVO NORDISK (DK) | 2003-06-12 | — | — | US | claimed |
| US-20020035106-A1 | Use of potassium channel agonists for reducing fat food consumption | NOVO NORDISK A/S (DK) | 2002-03-21 | — | — | US | claimed |
| US-20020028808-A1 | Use of potassium channel agonists for the treatment of cancer | NOVO NORDISK A/S (DK) | 2002-03-07 | — | — | US | claimed |
| US-20030235583-A1 | Combined use of a modulator of CD3 and a beta cell resting compound | NOVO NORDISK A/S (DK) | 2003-12-25 | — | — | US | disclosed |
| US-20030125323-A1 | Use of selective potassium channel openers | NOVO NORDISK A/S (DK) | 2003-07-03 | — | — | US | disclosed |
| US-20030109519-A1 | Use of selective potassium channel openers | NOVO NORDISK (DK) | 2003-06-12 | — | — | US | disclosed |
| US-20020035106-A1 | Use of potassium channel agonists for reducing fat food consumption | NOVO NORDISK A/S (DK) | 2002-03-21 | — | — | US | disclosed |
| US-20020028808-A1 | Use of potassium channel agonists for the treatment of cancer | NOVO NORDISK A/S (DK) | 2002-03-07 | — | — | US | disclosed |
| US-5889002-A | CENTRAL NERVOUS SYSTEM DISORDERS; CARDIOVASCULAR DISORDERS; RESPIRATORY SYSTEM DISORDERS; GASTROINTESTINAL DISORDERS; ENDOCRINAL DISEASES | NOVO NORDISK A/S (DK) | 1999-03-30 | — | — | US | disclosed |
| CN-1208417-A | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use | NOVO NORDISK AS (DK) | 1999-02-17 | — | — | CN | disclosed |
| EP-0876379-A1 | FUSED 1,2,4-THIADIAZINE AND FUSED 1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997026265-A1 | FUSED 1,2,4-THIADIAZINE AND FUSED 1,4-THIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1997-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125323-A1 | Use of selective potassium channel openers | KCNJ11, KCNJ1, KCNJ2 | ABCC8 73/4885KCNJ11 1/4885ADRA2A 613/4885 |
| US-20030109519-A1 | Use of selective potassium channel openers | KCNJ11, KCNJ2, KCNJ1 | ABCC8 63/4885KCNJ11 1/4885ADRA2A 578/4885 |
| US-20020028808-A1 | Use of potassium channel agonists for the treatment of cancer | KCNN3, KCNN1, KCNN2 | ABCC8 944/4885KCNJ11 7/4885ADRA2A 149/4885 |
| US-20030235583-A1 | Combined use of a modulator of CD3 and a beta cell resting compound | CD69, IAPP, CD4 | ABCC8 3372/4885KCNJ11 1274/4885ADRA2A 118/4885 |
| US-20020035106-A1 | Use of potassium channel agonists for reducing fat food consumption | KCNN3, KCNN2, KCNN1 | ABCC8 985/4885KCNJ11 13/4885ADRA2A 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.